Gregory D. Gutierrez, Ph.D.

Dr. Gregory Gutierrez is a senior associate in Goodwin’s Life Sciences and Technology groups.

Greg advises companies and investors on patent matters for life sciences and chemical innovations. He leverages his background in chemistry to help clients develop and manage global patent portfolios for their products across all stages of development, including after regulatory approval. He also supports clients during IP due diligence for various types of transactions, including M&A, venture financings, strategic partnerships, and public offerings.

Greg partners with companies of different sizes to build robust and valuable patent portfolios for their product candidates. His experience in the life sciences centers on strategies for small molecules, antibody-drug conjugates, peptides, oligonucleotides, and biomaterials and related Medtech. This encompasses patent protection for both composition of matter and next-generation inventions arising during product development, including course of treatment, solid forms/polymorphs, and drug product formulations. Greg is experienced in optimizing the exclusivities of FDA-approved products in anticipation of generic competition, including through patent term extension and Orange Book patent strategy. Greg also specializes in securing protection for deep tech advancements enabled by polymer chemistry and materials science, including inventions in functional materials and cleantech.

• Co-author, “Patents and intellectual property in drug discovery,” Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier, 2025.
• Co-author, “The Federal Circuit Raises the Section 112 Stakes for Chemical Structures in Seagen v. Daiichi,” Goodwin Alert, December 2025.
• Author, “PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims to be Unpatentable,” Life Sciences Perspectives, January 2024.